In the last 20 years, a multitude of prognostic and predictive markers have been tested, however only oestrogen receptor, progesterone receptor and HER2 are currently used to tailor the therapy of breast cancer patients (Goldhirsch et al, 2005). This evidence concerns the gene ERBB2 and breast cancer.